Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial

著者: Martin R. Gaudinski, Katherine V. Houser, Nicole A. Doria‐Rose, Grace Chen, Ro Shauna Rothwell, Nina M. Berkowitz, Pamela Costner, LaSonji A. Holman, Ingelise J. Gordon, Cynthia S. Hendel, Florence Kaltovich, Michelle Conan-Cibotti, Margarita Gomez Lorenzo, Cristina Carter, Sandra Sitar, Kevin Carlton, Jason G. Gall, Carolyn M. Laurençot, Bob C. Lin, Robert T. Bailer, Adrian B. McDermott, Sung‐Youl Ko, Amarendra Pegu, Young Do Kwon, Peter D. Kwong, Aryan M. Namboodiri, Janardan P. Pandey, Richard Schwartz, Frank Arnold, Zonghui Hu, Lily Zhang, Yunda Huang, Richard A. Koup, Edmund V. Capparelli, Barney S. Graham, John R. Mascola, Julie E. Ledgerwood, Floreliz Mendoza, Laura Novik, Kathy Zephir, William Whalen, Brenda Larkin, Jamie Saunders, Jennifer Cunningham, Carol Levinson, Xiaolin Wang, Sarah H. Plummer, Milalynn Victorino, Abidemi Ola, Catina Boyd, Nilusha Jayasinghe, Preeti Apte, Cora Trelles Cartagena, Renunda Hicks, Pernell Williams, Olga Vasilenko, Galina V. Yamshchikov, Maria Burgos Florez, Iris Pittman, Lúcio Gama, Joseph P. Casazza, Hope DeCederfelt, KC Cheng, Judy Stein - The Lancet 2019 被引用: 107